• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Wednesday, August 20, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Biology

DOD funding helps expand study of investigational drug to prevent ARDS in COVID

Bioengineer by Bioengineer
January 13, 2021
in Biology
Reading Time: 4 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

IMAGE

Credit: Cody Duty/UTHealth

Researchers evaluating whether an investigational oral drug, vadadustat, can help prevent acute respiratory distress syndrome (ARDS) in COVID-19 patients were awarded $5.1 million in funding from the U.S. Department of Defense (DOD) to expand the Phase II clinical trial at The University of Texas Health Science Center at HoustonQ (UTHealth).

Vadadustat is an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor, or HIF-PHI, designed to mimic the physiologic effect of altitude on oxygen availability. At higher altitudes, the body responds to lower oxygen availability with stabilization of HIF, which can lead to improved oxygen delivery to tissues. Stabilization of HIF can help to dampen alveolar inflammation, a key problem that patients with COVID-19-associated lung disease are facing when they develop ARDS. The drug is investigational in the U.S. but has been approved for use in Japan.

“It’s wonderful that we have COVID-19 vaccinations available now, but they won’t directly help patients who are already sick in the hospital or who will become sick in the future,” said Holger Eltzschig, MD, PhD, chair of the Department of Anesthesiology with McGovern Medical School at UTHealth. “In addition to vaccination, we direly need treatments to prevent ARDS, one of the deadliest complications of severe COVID-19. If we can arrest coronavirus infection at an earlier stage before the onset of lung complications that cause mortality, COVID-19 outcomes would be so much better.” Eltzschig is also director of the UTHealth Center for Perioperative Medicine and the John P. and Kathrine G. McGovern Distinguished University Chair.

The award was given through the DOD’s Peer Reviewed Medical Research Program as a COVID Clinical Trial Award. Only 4.2% of all applications submitted were awarded funding.

“This study could be critical for people in active duty with the armed forces as well as veterans,” Eltzschig said. “COVID-19 has had a particular impact on the Navy, where personnel on vessels such as aircraft carriers are in close environments and are unable to socially distance. If an innovative oral investigative therapy could prevent ARDS, that would be wonderful. Also, our country’s veterans tend to be older, have comorbidities, and are particularly suffering from dire consequences of COVID-19, so it would be fantastic to be able to help them as well.”

Vadadustat, being developed by Akebia Therapeutics, Inc., recently completed its global Phase III clinical trial development for the treatment of anemia due to chronic kidney disease in patients on dialysis and not on dialysis, and Akebia expects to submit a New Drug Application (NDA) for vadadustat to the FDA for these indications as early as possible in 2021.

Previously published preclinical studies led by Eltzschig, showed HIF stabilization can protect lungs in mice with ARDS. His basic and translation science team in anesthesia is collaborating with the clinical team of Ben Bobrow, MD, chair of Emergency Medicine at McGovern Medical School, to move the idea from bench to bedside to see if it can help COVID-19 patients.

“Dr. Bobrow and his clinical team of nurses and researchers helped us build up the trial quickly. I’ve never seen a clinical trial go from just an idea in March to enrolling patients in four months. It’s really remarkable and we couldn’t have done it without Akebia, UTHealth’s Center for Clinical and Translational Sciences, and the collaboration between Bobrow’s clinical group with my translational group,” Eltzschig said.

“So many people and departments at UTHealth, Memorial Hermann, and Harris Health have come together to bring this cutting-edge trial together faster than ever before to try to help people suffering from COVID-19 acute lung injury. Dr Eltzschig and I are inspired by the potential for this novel trial to make a major impact on COVID-19 patients,” said Bobrow, who is the John P. and Katherine G. McGovern Distinguished Chair in emergency medicine. Bobrow and Eltzschig are attending physicians at Memorial Hermann-Texas Medical Center.

The randomized trial began enrolling patients at Memorial Hermann-Texas Medical Center in July. The DOD funding helped the trial expand to Memorial Hermann-Southwest Hospital, Memorial Hermann Greater Heights Hospital, and Memorial Hermann Memorial City Medical Center, as well as Harris Health’s Lyndon B. Johnson Hospital. Currently, 75 patients have enrolled.

“It’s unclear how long COVID-19 will be prevalent so it is critical to expand the single center trial to other sites,” Eltzschig said.

###

The trial was initially funded by Akebia Therapeutics, Inc. and a donor grant to UTHealth’s Center for Clinical and Translational Sciences.

Other McGovern Medical School faculty involved in the study include Elizabeth Jones, MD; Samuel Luber, MD; George Williams, MD; Paulina Sergot, MD; David Robinson, MD; Marie-Francoise Doursout, PhD; Misha Granado, MPH, MS; Misty Ottman, RN; Yanyu Wang, PhD; Xiaoyi Yuan, PhD; Tingting Mills, PhD; Boyun Kim, PhD; Christian Noval, RN; James Wang, BS; Marka Lyons, MS; Robert Suchting, PhD; Charles Green, PhD; Victor Guaregua, BS; Synthea Horton, MS; Seungwon Choi, MD; Nabras Abdulrahman, MS.

The views expressed in this article are those of the author and may not reflect the official policy or position of the Department of the Army, Department of Defense, or the U.S. Government.

Media inquiries: 713-500-3030

Media Contact
Amy Laukka
[email protected]

Original Source

https://www.uth.edu/news/story.htm?id=2c7f7445-3390-4be1-a205-9297ce9dced7

Tags: Infectious/Emerging DiseasesMedicine/HealthPhysiologyPulmonary/Respiratory Medicine
Share12Tweet8Share2ShareShareShare2

Related Posts

Researchers Engineer Cells to Develop Biological Qubits in Pioneering Multidisciplinary Breakthrough

Researchers Engineer Cells to Develop Biological Qubits in Pioneering Multidisciplinary Breakthrough

August 20, 2025
Breakthrough Discoveries in Tendinopathy Treatment: Unveiling the Active Components of Rhizoma Coptidis

Breakthrough Discoveries in Tendinopathy Treatment: Unveiling the Active Components of Rhizoma Coptidis

August 20, 2025

Engineered ‘Superfood’ Supplement Enhances Bee Colony Reproduction, Aiding Conservation Efforts

August 20, 2025

Lead-Resistant Lizards in New Orleans Offer Insights into Fighting Lead Poisoning

August 20, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Molecules in Focus: Capturing the Timeless Dance of Particles

    141 shares
    Share 56 Tweet 35
  • Neuropsychiatric Risks Linked to COVID-19 Revealed

    80 shares
    Share 32 Tweet 20
  • Modified DASH Diet Reduces Blood Sugar Levels in Adults with Type 2 Diabetes, Clinical Trial Finds

    60 shares
    Share 24 Tweet 15
  • Predicting Colorectal Cancer Using Lifestyle Factors

    47 shares
    Share 19 Tweet 12

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Why Mental Health Guidance Can Increase Your To-Do List

Pilot Study Unveils How Music Therapy Eases Pain Following Pancreatic Surgery

UCLA and UC Santa Barbara’s BioPACIFIC MIP Secures Renewed NSF Funding to Propel AI-Driven Biobased Materials Innovation

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.